ODYSSEY ACQUISIT. A
Share · LU2355630455 (LSSI)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ODYSSEY ACQUISIT. A
No Price
Company Profile for ODYSSEY ACQUISIT. A Share
BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
Company Data
Name ODYSSEY ACQUISIT. A
Company BenevolentAI S.A.
Website
https://www.benevolent.com
Primary Exchange 
Lang & Schwarz
Lang & Schwarz
ISIN LU2355630455
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Kenneth Mulvany
Market Capitalization 11 Mio
Country United Kingdom
Currency EUR
Employees 0,2 T
Address 4-8 Maple Street, W1T 5HD London
IPO Date 2022-04-25
Ticker Symbols
| Name | Symbol |
|---|---|
| EURONEXT - EURONEXT AMSTERDAM | BAI.AS |
| Frankfurt | 2XA.F |
More Shares
Investors who hold ODYSSEY ACQUISIT. A also have the following shares in their portfolio:
